30 related articles for article (PubMed ID: 38547774)
1. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
Prado CM; Bekaii-Saab T; Doyle LA; Shrestha S; Ghosh S; Baracos VE; Sawyer MB
Br J Cancer; 2012 May; 106(10):1583-6. PubMed ID: 22510747
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.
Shoushtari AN; Khan S; Komatsubara K; Feun L; Acquavella N; Singh-Kandah S; Negri T; Nesson A; Abbate K; Cremers S; Musi E; Ambrosini G; Lee S; Schwartz GK; Carvajal RD
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771668
[TBL] [Abstract][Full Text] [Related]
4. Uveal melanoma: progress in molecular biology and therapeutics.
Li Y; Shi J; Yang J; Ge S; Zhang J; Jia R; Fan X
Ther Adv Med Oncol; 2020; 12():1758835920965852. PubMed ID: 33149769
[TBL] [Abstract][Full Text] [Related]
5. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
6. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P
J Clin Oncol; 2018 Apr; 36(12):1232-1239. PubMed ID: 29528792
[TBL] [Abstract][Full Text] [Related]
7. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
8. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A; Love S; Schuh A; Shanyinde M; Larkin JM; Plummer R; Nathan PD; Danson S; Ottensmeier CH; Lorigan P; Collins L; Wise A; Asher R; Lisle R; Middleton MR
Ann Oncol; 2014 May; 25(5):968-74. PubMed ID: 24567366
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
10. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ; Jackson R; Corrie P; Danson S; Evans TRJ; Ochsenreither S; Kumar S; Goodman A; Larkin J; Karydis I; Steven N; Lorigan P; Plummer R; Patel P; Psarelli E; Olsson-Brown A; Shaw H; Leyvraz S; Handley L; Rawcliffe C; Nathan P
Eur J Cancer; 2024 May; 202():114009. PubMed ID: 38547774
[TBL] [Abstract][Full Text] [Related]
11. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
